Kohlberg reinvests in PCI Pharma Services with Bain Capital, Mubadala, Partners Group

Excited to share Kohlberg’s strategic reinvestment in PCI Pharma Services in partnership with our new co-control investor Bain Capital plus continuing investors Mubadala and Partners Group. Also excited as the company enters its next phase of growth continuing to work with PCI CEO Salim Haffar and Chairman Matt Jennings. Since our lead investment in PCI in 2020, PCI has: ➡️Expanded into biologics, sterile fill-finish services for injectable drugs, and Advanced Drug Delivery, extending the company into the highest growth markets in pharma CDMO ➡️Invested organically and inorganically, including in cold chain infrastructure, regional facilities to support customers’ needs globally, and Advanced Drug Delivery injectable capabilities  ➡️Launched 450 drugs, now supporting 25% of the top 200 drugs on the market, including GLP-1s ➡️Doubled revenue, 4x’d its customer base, and grew from 3,000 to 8,000 employees ➡️Modernized through digital innovation, automation, and smart manufacturing ➡️Invested in its people, processes, and purpose-built facilities to meet growing global demand PCI today delivers an integrated state-of-the-art suite of modernized services from Phase 1 through commercial launch, spanning sterile fill-finish, drug delivery assembly, packaging, and global logistics. We look forward to supporting PCI as it continues to bring life-changing therapies to patients. 🔗 Full press release and details available here: https://lnkd.in/d8_2fzfp